RxDoctor Payments Data

Ryan Little, NP

Family · Binghamton, NYNPI 1215098025

Payments from drug & device makers

$17,705in general payments, 2019–2025

Across 920 payments — averaging $19.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Novo Nordisk$3K
  • Edwards Lifesciences$2K
  • GSK$1K
  • AstraZeneca$1K
  • Viiv Healthcare Company$962
  • plus $6K from 37 others

What the payments were for

  • Food & beverage$17,705100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,705 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$41,007
Medicare patients
194
Services billed
675

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban115$155,283
JardianceEmpagliflozin87$133,814
BiktarvyBictegrav/Emtricit/Tenofov Ala18$122,034
OzempicSemaglutide69$100,051
Trelegy ElliptaFluticasone/Umeclidin/Vilanter76$87,493
DovatoDolutegravir Sodium/Lamivudine24$81,373
JulucaDolutegravir/Rilpivirine14$60,250
RybelsusSemaglutide29$57,375
FarxigaDapagliflozin Propanediol30$42,628
DescovyEmtricitabine/Tenofov Alafenam11$38,879
XareltoRivaroxaban18$28,532
MounjaroTirzepatide22$24,820
JanuviaSitagliptin Phosphate16$23,407
EntrestoSacubitril/Valsartan25$22,762
TradjentaLinagliptin15$22,013

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$426$166,515113 claims
Novo NordiskOzempic, Rybelsus$3,010$157,42698 claims
PfizerEliquis$355$155,283115 claims
Viiv Healthcare CompanyDovato, Juluca$962$141,62338 claims
GSKTrelegy Ellipta, Breo Ellipta$1,264$100,515100 claims
AstraZenecaFarxiga$1,045$42,62830 claims
Johnson & JohnsonXarelto$233$28,53218 claims
Lilly USA, LLCMounjaro$661$24,82022 claims
MerckJanuvia$159$23,40716 claims
NovartisEntresto$76$22,76225 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$81$3,70711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.

Other family in Binghamton

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →